Skip to main content
Premium Trial:

Request an Annual Quote

PPO MultiPlan Covering GenomeDx's Prostate Cancer Test

NEW YORK (GenomeWeb) – Prostate cancer diagnostics firm GenomeDx today announced it has signed a contract with MultiPlan for diagnostic laboratory testing.

As result of the deal, members of the preferred provider organization will have access to GenomeDx's Decipher Prostate Cancer Classifier, which measures a patient's biological risk of developing metastatic prostate cancer. MultiPlan has more than 500,000 providers in its network.

In June, GenomeDx and Prime Health Services inked a deal providing coverage for Decipher, and more than 190 million covered lives now have access to GenomeDx's test, the San Diego-based company said.

Decipher uses whole-genome analysis to profile RNA expression signatures to measure the aggressiveness of prostate cancer in patients who have had a prostatectomy. The test provides information that is distinct from PSA information and other clinical risk factors.

The Scan

NFTs for Genome Sharing

Nature News writes that non-fungible tokens could be a way for people to profit from sharing genomic data.

Wastewater Warning System

Time magazine writes that cities and college campuses are monitoring sewage for SARS-CoV-2, an approach officials hope lasts beyond COVID-19.

Networks to Boost Surveillance

Scientific American writes that new organizations and networks aim to improve the ability of developing countries to conduct SARS-CoV-2 genomic surveillance.

Genome Biology Papers on Gastric Cancer Epimutations, BUTTERFLY, GUNC Tool

In Genome Biology this week: recurrent epigenetic mutations in gastric cancer, correction tool for unique molecular identifier-based assays, and more.